Chunhe Wang

Chunhe Wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
YCYi-Li Chen
Yi-Li Chen
YCYue Cui
Yue Cui
XLXinyuan Liu
Xinyuan Liu
GLGuojian Liu
Guojian Liu
XDXingchen Dong
Xingchen Dong
MFMeiqing Feng
Meiqing Feng
Activation of the programmed cell death protein 1 and programmed cell death ligand 1 (PD-1/PD-L1) signaling axis plays important roles in intrinsic or acquired resistance to human epidermal growth factor receptor 2 (HER2)-directed therapies in the clinic. Therefore, therapies simultaneously targeting both HER2 and PD-1/PD-L1 signaling pathways are of great significance. Here, aiming to direct the anti-PD-L1 responses toward HER2-expressing tumor cells, we constructed a humanized bispecific IgG1 subclass antibody targeting both HER2 and PD-L1 (HER2/PD-L1; BsAb), which displayed satisfactory purity, thermostability, and serum stability. We found that BsAb showed enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity in vitro. In the late phase of peripheral blood mononuclear cell (PBMC)-humanized HER2+ tumor xenograft models, BsAb showed superior therapeutic efficacies as compared with monoclonal antibodies (mAbs) or combination treatment strategies. In cynomolgus monkeys, BsAb showed favorable pharmacokinetics and toxicity profiles when administered at a 10 mg/kg dosage. Thus, HER2/PD-L1 BsAb was demonstrated as a potentially effective option for managing HER2+ and trastuzumab-resistant tumors in the clinic. We propose that the enhanced antitumor activities of BsAb in vivo may be due to direct inhibition of HER2 signaling or activation of T cells.

12 December 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
TMTingting Ma
Tingting Ma
BCBei Cao
Bei Cao
LHLei Huang
Lei Huang
YYYuanxun Yang
Yuanxun Yang
YGYan Geng
Yan Geng
JLJuan Li
Juan Li
Purpose: To evaluate the safety, tolerability, pharmacokinetics and immunogenicity of DS002 injection, an anti-nerve growth factor (anti-NGF) monoclonal antibody for treating pain conditions, in healthy Chinese subjects.Methods: This study was a single-center, randomized, double-blind, single-dose escalation, placebo-controlled design (CTR20210155). A total of 53 healthy subjects, 27 male and 26 female, were enrolled in this study, and one subject withdrew from the study before administration. Seven dose groups were set up, which were 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 7.0 mg, 12.0 mg and 20.0 mg, respectively. The drug was administered by single subcutaneous injection. Four subjects were enrolled in the first dose group (0.5 mg) received DS002. Other dose groups enrolled eight subjects each, six of whom received DS002 while the other two received a placebo. Safety, tolerability, pharmacokinetic parameters and immunogenicity of DS002 were assessed.Results: DS002 was well tolerated; all adverse events were Grade 1–2, and did not reach the termination standard of dose increment within the range of 0.5–20.0 mg. Adverse event rates were generally similar across treatments. After a single subcutaneous injection, the median Tmax in different dose groups ranged 167.77–337.38 h; mean t1/2 ranged 176.80–294.23 h, the volume of distribution (Vz) ranged 5265.42–7212.00 ml, and the clearance rate (CL) ranged 12.69–24.75 ml/h. In the dose range of 0.5–20.0 mg, Cmax ranged from 51.83 ± 22.74 ng/ml to 2048.86 ± 564.78 ng/ml, AUC0-t ranged from 20615.16 ± 5698.28 h·ng/mL to 1669608.11 ± 387246.36 h·ng/mL, and AUC0-inf ranged from 21852.45 ± 5920.21 h·ng/mL to 1673504.66 ± 389106.13 h·ng/mL. They all increased with dose escalation, and Cmax and AUC0-t did not have a significant dose-linear relationship, whilst AUC0-t was not dose-dependent at all. anti-drug antibody test results of each group of all subjects in this trial were negative.Conclusion: DS002 showed satisfactory safety within the dose range of 0.5 mg–20.0 mg. The absorption and metabolism of DS002 were slow, it exhibited a low volume of distribution and the clearance rate was low. These data suggest that DS002, by blocking nerve growth factor, is expected to become a novel, safe and non-addictive treatment for pain conditions.

26 November 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MPMin Pei
Min Pei
XDXiao-Dong Dai
Xiao-Dong Dai
XJXiao-Fan Jiang
Xiao-Fan Jiang
CYCai-Yi Yuan
Cai-Yi Yuan
JTJie Tan
Jie Tan
CWChunhe Wang
Chunhe Wang
Introduction: Blockade of the CD47/SIRPa axis has emerged as a promising approach to enhance macrophage-mediated anti-tumor activities in cancer immunotherapy. However, the clinical application of early CD47 antibodies has been associated with significant hematotoxicities, including hemagglutination, anemia, and thrombopenia. Although several CD47 antibodies have generally avoided hemagglutination, anemia, and thrombopenia remain, potentially mediated by enhanced phagocytosis of erythrocytes and thrombocytes. Methods: 1B2–10 is a humanized CD47-neutralizing antibody generated by mouse immunization and phage display technology. Its efficacy and safety were evaluated using in vitro assays, tumor xenograft models, and studies in cynomolgus monkeys. In silico modeling and mutagenesis analyses were performed to identify the 1B2-10 binding epitopes. Results: In vitro , 1B2–10 exhibited minimized binding to erythrocytes and thrombocytes, did not induce hemagglutination, and reduced erythrocyte phagocytosis. It enhanced macrophage-mediated phagocytosis of tumor cells and showed potent antitumor effects as a monotherapy or in combination with a PD-1 antibody in tumor models. In cynomolgus monkeys, single doses of 1B2–10 at 120 mg/kg and repeated doses at 100 mg/kg were well-tolerated, with no significant hematological toxicities observed. In silico studies revealed the molecular basis for reduced erythrocyte binding, demonstrating that two critical N-linked glycans sterically masked epitopes. Discussion: These findings suggest that 1B2-10 demonstrates a favorable efficacy and safety profile, indicating great therapeutic potential for cancer. Based on these studies, 1B2–10 has been renamed as DS003 and is currently advancing through Phase I clinical trials in China to further evaluate its safety profile and preliminary efficacy in human subjects.

29 September 2022 in Bio-Protocol
Verified
Journal Article
Closed access
MPMin Pei
Min Pei
LTLei Tang
Lei Tang
YWYao Wang
Yao Wang
WWWeitao Wu
Weitao Wu
CWChunhe Wang
Chunhe Wang
YCYi-Li Chen
Yi-Li Chen
An open platform for life scientists to share, find,and discuss research protocols

10 March 2026 in Protein Expression and Purification
Verified
Journal Article
Closed access
APAiling Pan
Ailing Pan
CYCaiyi Yuan
Caiyi Yuan
YWYaru Wang
Yaru Wang
CQChengcheng Qiu
Chengcheng Qiu
GLGuojian Liu
Guojian Liu
CWChunhe Wang
Chunhe Wang